Hyperion Therapeutics Announces First Patient Enrolled In Trial In Children With Urea Cycle Disorders

Hyperion Therapeutics announced that the first patient has been enrolled in a clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate) in children ages 6-17 with urea cycle disorders (UCD). The study will evaluate the safety, tolerability, and ammonia control of glycerol phenylbutyrate compared to BUPHENYL® (sodium phenylbutyrate).